Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 207

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies

Open access
den Hollander, Anneke I., Black, Aaron, Bennett, Jean, Cremers, Frans P.M. · 2010 · Journal of Clinical Investigation

Abstract

Nonsyndromic recessive retinal dystrophies cause severe visual impairment due to the death of photoreceptor and retinal pigment epithelium cells.These diseases until recently have been considered to be incurable.Molecular genetic studies in the last two decades have revealed the underlying molecular causes in approximately two-thirds of patients.The mammalian eye has been at the forefront of therapeutic trials based on gene augmentation in humans with an early-onset nonsyndromic recessive retinal dystrophy due to mutations in the retinal pigment epithelium-specific protein 65kDa (RPE65) gene.Tremendous challenges still lie ahead to extrapolate these studies to other retinal disease-causing genes, as human gene augmentation studies require testing in animal models for each individual gene and sufficiently large patient cohorts for clinical trials remain to be identified through cost-effective mutation screening protocols. Phenotypes of inherited nonsyndromic retinal diseasesGeneralized and/or peripheral retinal dystrophies.Retinitis pigmentosa (RP) represents the most frequent cause of inherited visual impairment, with a worldwide prevalence of 1:4,000 (1).It encompasses a clinically heterogeneous group of progressive disorders that primarily affect the function of the photoreceptors and the RPE (2).There is a large variability in the age of onset, progression, retinal appearance, and final visual outcome.Pigment granules from the RPE migrate to perivascular sites of the neural retina secondary to photoreceptor death, forming the hallmark "bone spicules" (Figure 1C).The attenuation of the retinal arterioles and veins probably also represents a secondary effect of photoreceptor cell death.Initially, rods are predominantly affected, resulting in night blindness and tunnel vision.Later in the disease process, cones also are affected, which can result in complete blindness (1).Thirty percent of RP patients show AR inheritance, 20% show AD inheritance, and 10% show XL inheritance (2).Approximately 40% of RP patients represent isolated cases.Conflict of interest: Jean Bennett is a co-inventor on the pending patent "A Method of Treating or Retarding the Development of Blindness" but waived any financial interest in this technology in 2002.Jean Bennett presented a seminar at Novartis in 2009.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci42258

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 207

Metadata

Authors
den Hollander, A. I., Black, A., Bennett, J., & Cremers, F. P. M.
Venue
Journal of Clinical Investigation
Published
2010-09-01
Volume
120
Issue
9
Pages
3042-3053
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2042293587
Cited by
207
References
26
FWCI
7.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. https://app.cochat.ai/papers/10.1172/jci42258
The paper
den Hollander, A. I., Black, A., Bennett, J., & Cremers, F. P. M. (2010). Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. Journal of Clinical Investigation. https://doi.org/10.1172/jci42258

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.